22.728 articles found

Effects of acute and chronic dopaminergic treatment on motor and non-motor function in the hemi-Parkinsonian rat

Murphy EM.

· 2014-01-01

Characterisation of DISC1 ubiquitination and its potential as a therapeutic intervention for psychiatric disorders

Yalla KC.

· 2014-01-01

Genetic epidemiology of psychotic symptoms and their treatment in dementia

Creese B.

· 2014-01-01

Alternating-lever-cyclic-ratio schedule analysis of oligomeric peptide effects on behaviour and putative pharmacotherapeutic interventions

Barbour B.

· 2014-01-01

Behavioural investigation into whether L-DOPA, the current 'gold standard' pharmacotherapy for Parkinson's disease, can be improved by optimising its treatment strategies

Tayarani-Binazir KA.

· 2014-01-01

Investigating group III metabotropic glutamate receptors as novel therapeutic targets in Parkinson's disease and Levodopa-induced dyskinesia

Finlay CJ.

· 2014-01-01

Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.

Hill AL, Sun B, McDonnell DP.

Clin Schizophr Relat Psychoses · 2014-01-01

PMID: 23428782

Targeting CNS transporters for treatment of neurodegenerative diseases.

Jedlitschky G, Grube M, Mosyagin I, Kroemer HK, Vogelgesang S.

Curr Pharm Des · 2014-01-01

DOI: 10.2174/13816128113199990460PMID: 23789959

Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review.

Velayudhan L, Van Diepen E, Marudkar M, Hands O, Suribhatla S, Prettyman R, Murray J, Baillon S, Bhattacharyya S.

Curr Pharm Des · 2014-01-01

DOI: 10.2174/13816128113199990434PMID: 23829360

The treatment of tremor.

Schneider SA, Deuschl G.

Neurotherapeutics · 2014-01-01

DOI: 10.1007/s13311-013-0230-5PMID: 24142589

Animal models of Parkinson's disease: a gateway to therapeutics?

Le W, Sayana P, Jankovic J.

Neurotherapeutics · 2014-01-01

DOI: 10.1007/s13311-013-0234-1PMID: 24158912

α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.

Rott R, Szargel R, Shani V, Bisharat S, Engelender S.

CNS Neurol Disord Drug Targets · 2014-01-01

DOI: 10.2174/18715273113126660195PMID: 24168368